Want to see MMED full AI Analyst Report?
MMED Stock Chart & Stats
$20.10
$0.92(4.65%)
At close: 4:00 PM EDT
$20.10
$0.92(4.65%)
Day’s Range― - ―
52-Week Range$10.65 - $24.43
Previous Close$20.7
Volume1.31M
Average Volume (3M)2.27M
Market Cap
$5.62B
Enterprise Value$4.92K
Total Cash (Recent Filing)$207.00M
Total Debt (Recent Filing)$59.00M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Jun 09, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding281,349,950
10 Day Avg. Volume3,014,458
30 Day Avg. Volume2,265,741
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)0.94
Price to Sales (P/S)1.09
P/FCF Ratio-8.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$26.40Price Target Upside31.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.67
Revenue Forecast (FY)$3.44B
Bulls Say, Bears Say
Bulls Say
Revenue And Recurring AdoptionStrong growth across pumps, continuous glucose monitoring and consumables indicates broad product adoption rather than reliance on one offering. The 82% recurring-revenue mix can support customer retention, visibility and durable expansion as the installed base and CGM attachment rates increase.
Low Leverage And LiquidityA debt-free position, substantial cash and available revolver provide financial flexibility while MiniMed invests in products and completes its stand-alone build-out. This conservative funding profile reduces balance-sheet strain and gives management capacity to support growth through near-term volatility.
Product Pipeline And GuidanceRaised organic growth guidance and multiple advancing products support a multi-year innovation cycle in pumps, sensors and algorithms. Planned launches and clinical milestones can broaden the portfolio, attract new users and reinforce the company’s competitive position in diabetes management.
Bears Say
Widening LossesRapid revenue growth has not yet translated into sustainable bottom-line profitability. Widening losses and a net margin well below zero indicate that the cost structure remains heavy, limiting internally funded investment and increasing the execution burden required to convert growth into earnings.
Cash BurnThe reversal from positive operating cash flow to substantial cash consumption weakens the quality of current growth and raises funding risk if it persists. Continued negative free cash flow could constrain product investment, reduce flexibility and make successful operating execution more important.
Margin And Separation HeadwindsA lower-margin product mix can weigh on gross profitability as Simplera expands, while stand-alone separation work and remaining transition agreements create ongoing operating complexity. These pressures may delay margin normalization and make the reaffirmed profitability targets harder to achieve.
MiniMed Group, Inc. News
MMED FAQ
What was MiniMed Group, Inc.’s price range in the past 12 months?
MiniMed Group, Inc. lowest stock price was $10.65 and its highest was $24.43 in the past 12 months.
What is MiniMed Group, Inc.’s market cap?
MiniMed Group, Inc.’s market cap is $5.62B.
When is MiniMed Group, Inc.’s upcoming earnings report date?
MiniMed Group, Inc.’s upcoming earnings report date is Jun 09, 2027 which is in 254 days.
How were MiniMed Group, Inc.’s earnings last quarter?
MiniMed Group, Inc. released its earnings results on Sep 01, 2026. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.124 by -$0.124.
Is MiniMed Group, Inc. overvalued?
According to Wall Street analysts MiniMed Group, Inc.’s price is currently Undervalued.
Does MiniMed Group, Inc. pay dividends?
MiniMed Group, Inc. does not currently pay dividends.
What is MiniMed Group, Inc.’s EPS estimate?
MiniMed Group, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MiniMed Group, Inc. have?
MiniMed Group, Inc. has 281,349,950 shares outstanding.
What happened to MiniMed Group, Inc.’s price movement after its last earnings report?
MiniMed Group, Inc. reported an EPS of $0 in its last earnings report, missing expectations of $0.124. Following the earnings report the stock price went up 10.661%.
Which hedge fund is a major shareholder of MiniMed Group, Inc.?
Currently, no hedge funds are holding shares in MMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MiniMed Group, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.40 (31.34% Upside)
$26.40 (31.34% Upside)
Blogger Sentiment
Bullish
MMED Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 192.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 20.2%
Last 30 Days ▲ 20.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Learn more about TipRanks Smart Score
Company Description
MiniMed Group, Inc.
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories. These innovations are crafted to enable both patients and healthcare providers to accurately monitor and precisely regulate blood glucose levels. The enterprise was established in 1983 by Alfred E. Mann and is currently headquartered in Northridge, California.
MMED Company Deck
MMED Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive, with robust organic revenue growth, accelerating U.S. performance, broad international momentum, improving operating metrics, multiple pipeline milestones delivered ahead of schedule and raised revenue guidance. Reported EBITDA margin and free cash flow were affected by foreign exchange and stand-alone separation activities, while Simplera's mix remains a current-year gross-margin headwind, but management reaffirmed full-year EBITDA margin guidance and described the underlying business performance as strong.View all MMED earnings summariesMMED Stock 12 Month Forecast
Average Price Target
$26.40
▲(31.34% Upside)
Technical Analysis
Addus Homecare
―
Option Care Health
―
Brookdale Senior Living
―
National Healthcare
―
Aveanna Healthcare Holdings
―
Ownership Overview
0.70% Insiders
<0.01% Mutual Funds
3.52% Other Institutional Investors
94.65% Public Companies and
Individual Investors